Latest News for HNSA.ST
/PRNewswire/ -- Hansa Biopharma AB ("Hansa" or "the Company") (NASDAQ Stockholm: HNSA) and SERB S.A. ("SERB") today announced required regulatory approvals
Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation
/PRNewswire/ -- Hansa Biopharma AB, "Hansa" (NASDAQ STOCKHOLM: HNSA), today announced positive topline results from the European 20-HMedIdeS-19 Post
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 PR News
Hansa Biopharma enters into â¬115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA PR New
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for HNSA.ST.
Senate Trading
No Senate trades found for HNSA.ST.
U.S. House Trading
No House trades found for HNSA.ST.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.